ELIS (ELIS) ETF Price, Holdings & News

Technical Score (1D)

SELL

News Sentiment

BULLISH

What's happening to ELIS today?

ELIS is currently experiencing positive momentum, primarily driven by developments at LLY. The recent announcement of positive Phase 3 results for Retevmo in lung cancer, alongside strong GLP-1 demand, is bolstering LLY's outlook. This positive sentiment is reinforced by LLY's proactive measures to build a substantial pre-launch inventory of orforglipron, its oral weight loss drug, to meet anticipated demand. Increased institutional investment, including a significant stake increase by JPMorgan, reflects growing confidence in LLY's growth trajectory. However, Liberty One's reduction in its position in Lamb Weston, a top holding for the firm, introduces a note of caution. LLY is also expanding beyond GLP-1 with RNA-based cancer therapies and AI-driven drug development. Traders should monitor LLY's presentation at the TD Cowen Health Care Conference on March 2, 2026, for further insights into its evolving strategy and potential impact on the ETF.

News Sentiment Analysis

Sentiment gathered from recent headlines

82/100

Strong NegativeNeutralStrong Positive

BULLISH

Recent News Coverage (Top ETF Holdings)

ETF: ELIS

0 articles

Last updated: February 15, 2026

ELIS ETF: Navigating Inverse Exposure to Eli Lilly

The Direxion Daily LLY Bear 1X Shares (ELIS) ETF offers a unique investment proposition by providing inverse exposure to Eli Lilly and Company (LLY). This structure means the fund aims to deliver the opposite of LLY's daily performance. The fund achieves this through financial instruments like swap agreements and options, targeting a 1X daily inverse exposure to LLY.

Given its inverse nature, ELIS is inherently designed for short-term trading strategies rather than long-term investment. The fund's non-diversified status, with 100% of its holdings in LLY, amplifies its sensitivity to the pharmaceutical company's stock movements. Investors should carefully consider their risk tolerance and investment horizon before engaging with this ETF.

Inverse Exposure

ELIS is structured to provide inverse (or short) exposure to Eli Lilly. This means the fund's value is expected to increase when LLY's stock price decreases, and vice versa.

The fund's investment strategy relies on financial instruments such as swap agreements and options to achieve its inverse exposure objective.

This structure makes ELIS suitable for investors looking to profit from, or hedge against, a potential decline in Eli Lilly's stock price over a short-term period.

Concentrated Holdings

ELIS holds a highly concentrated portfolio, with 100% of its assets invested in Eli Lilly and Company (LLY).

This concentration means the fund's performance is directly tied to the performance of LLY, increasing both the potential for gains and the risk of losses.

Investors should be aware of this concentration and its implications for portfolio diversification and risk management.

Trading Strategy

ELIS is designed for short-term trading strategies, not long-term investment. Its daily inverse exposure makes it sensitive to daily market fluctuations.

The fund's performance is reset daily, meaning returns are not compounded over time. This structure is best suited for active traders.

Investors should monitor their positions frequently and be prepared to adjust their strategy based on market conditions and their risk tolerance.

Pharma Sector Focus

ELIS is categorized within the pharma sector, specifically targeting the performance of Eli Lilly and Company.

This sector focus means the fund's performance is heavily influenced by developments within the pharmaceutical industry, including drug approvals, clinical trial results, and regulatory changes.

Investors should consider the broader pharmaceutical market trends and the specific dynamics of LLY when evaluating ELIS.

Risk Considerations

As an inverse ETF, ELIS carries significant risks. It is designed to perform in the opposite direction of its underlying asset, which can lead to substantial losses if the market moves against the investor's expectations.

The fund's non-diversified nature, with its sole focus on LLY, amplifies these risks. Investors should be prepared for potentially high volatility.

Leverage, through the use of financial instruments, can magnify both gains and losses. Investors should fully understand the risks before investing.

Positioning ELIS

Given its inverse and non-diversified nature, ELIS is best suited for short-term trading strategies. Investors should carefully monitor their positions and be prepared to adjust their strategy based on market conditions and their risk tolerance. Consider using ELIS to hedge against potential downturns in Eli Lilly's stock price. Due to its daily reset, ELIS is not designed for long-term holding.

What Influences ELIS?

ELIS seeks daily inverse exposure to Eli Lilly (LLY), so its performance hinges on the pharmaceutical company's stock movements. Understanding the drivers of LLY's price is therefore crucial for interpreting ELIS's potential gains or losses.

LLY's Drug Pipeline

The success or failure of LLY's clinical trials and new drug approvals directly impacts its stock price, which ELIS inversely tracks.

Positive developments in LLY's pipeline, such as successful trial results or FDA approvals, can lead to a price increase in LLY, causing ELIS to decline, and vice versa.

Inverse Daily Leverage

ELIS employs daily inverse leverage, meaning its returns are designed to be the opposite of LLY's daily performance, magnified by a factor of one.

This structure means that ELIS is highly sensitive to daily price fluctuations in LLY; investors should be aware of the compounding effects of daily returns, especially during periods of high volatility.

Sector Sentiment

Broader sentiment towards the pharmaceutical sector can influence LLY's stock price, impacting ELIS.

Positive news or increased investor confidence in the pharma industry may lift LLY, negatively affecting ELIS; conversely, negative sector news could benefit ELIS.

Key insight: ELIS's performance is primarily determined by the daily price movements of LLY and the broader sentiment toward the pharmaceutical sector. Investors should carefully monitor these factors when considering an investment in ELIS.

Key Metrics for ELIS

ELIS offers inverse exposure to Eli Lilly, making it crucial to monitor factors impacting the underlying stock and the fund's operational efficiency. Key metrics help assess the fund's ability to deliver on its inverse objective and manage associated risks.

Daily Tracking: This assesses how closely ELIS mirrors the inverse daily performance of Eli Lilly. Significant deviations suggest potential issues with the fund's derivative instruments or operational efficiency. Consistent tracking is vital for achieving the intended inverse exposure to LLY.

Holdings Concentration: Given the 100% allocation to Eli Lilly, this metric highlights the fund's concentrated risk. Investors should monitor LLY's price movements closely. The fund's performance is directly tied to the pharmaceutical company's stock performance, amplifying both gains and losses.

Expense Ratio: The expense ratio represents the annual cost of owning ELIS. A higher expense ratio can erode returns, especially in a leveraged fund. Investors should compare the expense ratio to similar inverse ETFs to understand the fee drag on performance.

Volatility Regime: This monitors the volatility of Eli Lilly's stock, as ELIS's inverse performance is amplified by LLY's price swings. Increased volatility can lead to larger daily percentage changes, impacting the fund's returns. Investors should assess their risk tolerance in relation to LLY's volatility.

Liquidity & Spreads: This assesses the ease with which ELIS shares can be bought and sold. Wide bid-ask spreads can increase trading costs, especially during volatile periods. Monitoring liquidity is crucial for managing entry and exit points, particularly in a leveraged fund like ELIS.

Underlying Trend: This monitors the trend of Eli Lilly's stock price. Since ELIS aims to provide inverse exposure, a sustained upward trend in LLY will negatively impact the fund. Investors should use this to gauge the fund's potential for gains or losses.

Risk Factors to Monitor

ELIS seeks daily inverse exposure to Eli Lilly and Company (LLY). This strategy exposes investors to significant volatility and the potential for substantial losses, especially during periods of sustained upward movement in the underlying asset.

Single-Stock Concentration
The fund's performance is entirely dependent on the price movements of Eli Lilly and Company (LLY), as it holds a 100% position in the stock. Any adverse news, regulatory changes, or negative developments specific to LLY will directly and significantly impact the fund's value. This concentration amplifies the potential for losses compared to a diversified portfolio.
Compounding Risk
Due to the fund's 1X daily inverse objective, returns are reset daily. This means that the fund's performance over periods longer than one day can deviate significantly from the inverse of LLY's performance due to the effects of compounding. During periods of high volatility, this effect can lead to substantial losses, even if LLY's overall trend is relatively flat.
Volatility Drag
The fund's inverse exposure is particularly vulnerable to volatility. As LLY's price fluctuates, the fund's daily rebalancing can lead to a 'volatility drag,' where the fund loses value even if LLY's price remains relatively unchanged over time. This effect is exacerbated during periods of high market volatility, potentially leading to significant underperformance.
Tracking Error
The fund's ability to perfectly track the inverse performance of LLY is subject to tracking error. This can arise from various factors, including fund expenses, the use of derivatives, and the daily rebalancing process. The fund's performance may deviate from the inverse of LLY's daily returns, leading to unexpected outcomes for investors.
Leverage Decay
The fund's daily reset mechanism means that it is subject to 'beta slippage' or 'decay'. If LLY trends in one direction over a period, the fund will likely underperform its inverse target due to the daily reset. This effect is most pronounced during sustained trends in the underlying asset, leading to losses for the fund.
Expense Ratio Impact
The fund's expense ratio and other structural costs will erode returns over time. These fees are a direct drag on performance, and the fund must generate returns sufficient to cover these costs. If LLY's performance is relatively flat or experiences only modest gains, the fund may still generate losses due to the impact of these expenses.

Frequently Asked Questions

What is the investment objective of ELIS?

ELIS aims to deliver 1x daily inverse exposure to Eli Lilly and Company (LLY). This means the fund seeks to provide the opposite of LLY's daily performance. The fund is designed for short-term trading and not for long-term investment due to daily compounding effects.

What is the structure of the ELIS ETF?

ELIS is structured as a leveraged ETF, specifically designed to provide inverse exposure. It achieves this through financial instruments like swaps and options. Investors should understand that leveraged ETFs reset daily, which can lead to significant differences in returns over longer periods compared to the underlying asset.

What are the top holdings of ELIS?

ELIS holds a concentrated position, with 100% of its portfolio invested in financial instruments designed to provide inverse exposure to Eli Lilly and Company (LLY). This concentration means the fund's performance is highly sensitive to the daily price movements of LLY. Investors should monitor LLY's price action closely.

What are the risks associated with investing in ELIS?

Investing in ELIS carries significant risks, including daily compounding, leverage, and market volatility. Because it is an inverse ETF, ELIS is designed to profit when LLY declines in value. However, the fund's performance can diverge significantly from the inverse of LLY's performance over time due to daily resets and market fluctuations.

How does the expense ratio affect ELIS returns?

The expense ratio of ELIS represents the annual fees charged to manage the fund. These fees are deducted from the fund's assets and can impact overall returns. Investors should consider the expense ratio alongside the fund's performance and investment strategy when evaluating ELIS.

How volatile is ELIS?

ELIS is expected to be highly volatile due to its leveraged and inverse nature, combined with the inherent volatility of the underlying asset, LLY. The fund's daily reset mechanism amplifies both gains and losses. Investors should be prepared for potentially significant price swings.

What is the relationship between ELIS and LLY?

ELIS is designed to move inversely to the daily performance of Eli Lilly and Company (LLY). When LLY's stock price increases, ELIS is expected to decrease, and vice versa. However, due to daily compounding and leverage, the fund's performance may not perfectly mirror the inverse of LLY's long-term returns.

What is the 52-week high and low for ELIS?

The 52-week high for ELIS is 31.3034, and the 52-week low is 16.4. These figures provide context for the fund's price range over the past year. Investors can use this information to assess the fund's recent performance relative to its historical trading range.

Who might consider investing in ELIS?

ELIS is generally suitable for sophisticated investors with a short-term trading horizon who understand the risks of leveraged and inverse ETFs. It may appeal to those who anticipate a decline in the price of Eli Lilly and Company (LLY) and want to profit from that expectation. Due to its structure, it is not appropriate for long-term investors.

How liquid is ELIS?

Liquidity for ELIS depends on trading volume and market conditions. Investors should check the fund's average daily trading volume to assess its liquidity. High trading volume generally indicates greater liquidity, making it easier to buy and sell shares at desired prices. However, liquidity can change, especially during periods of market stress.

News Sentiment Analysis

Sentiment gathered from recent headlines

82/100

Strong NegativeNeutralStrong Positive

BULLISH

Recent News Coverage (Top ETF Holdings)

ETF: ELIS

0 articles

Last updated: February 15, 2026

ELIS ETF: Navigating Inverse Exposure to Eli Lilly

Inverse Exposure

ELIS is structured to provide inverse (or short) exposure to Eli Lilly. This means the fund's value is expected to increase when LLY's stock price decreases, and vice versa.

The fund's investment strategy relies on financial instruments such as swap agreements and options to achieve its inverse exposure objective.

This structure makes ELIS suitable for investors looking to profit from, or hedge against, a potential decline in Eli Lilly's stock price over a short-term period.

Concentrated Holdings

ELIS holds a highly concentrated portfolio, with 100% of its assets invested in Eli Lilly and Company (LLY).

This concentration means the fund's performance is directly tied to the performance of LLY, increasing both the potential for gains and the risk of losses.

Investors should be aware of this concentration and its implications for portfolio diversification and risk management.

Trading Strategy

ELIS is designed for short-term trading strategies, not long-term investment. Its daily inverse exposure makes it sensitive to daily market fluctuations.

The fund's performance is reset daily, meaning returns are not compounded over time. This structure is best suited for active traders.

Investors should monitor their positions frequently and be prepared to adjust their strategy based on market conditions and their risk tolerance.

Pharma Sector Focus

ELIS is categorized within the pharma sector, specifically targeting the performance of Eli Lilly and Company.

This sector focus means the fund's performance is heavily influenced by developments within the pharmaceutical industry, including drug approvals, clinical trial results, and regulatory changes.

Investors should consider the broader pharmaceutical market trends and the specific dynamics of LLY when evaluating ELIS.

Risk Considerations

The fund's non-diversified nature, with its sole focus on LLY, amplifies these risks. Investors should be prepared for potentially high volatility.

Leverage, through the use of financial instruments, can magnify both gains and losses. Investors should fully understand the risks before investing.

Positioning ELIS

What Influences ELIS?

LLY's Drug Pipeline

The success or failure of LLY's clinical trials and new drug approvals directly impacts its stock price, which ELIS inversely tracks.

Positive developments in LLY's pipeline, such as successful trial results or FDA approvals, can lead to a price increase in LLY, causing ELIS to decline, and vice versa.

Inverse Daily Leverage

ELIS employs daily inverse leverage, meaning its returns are designed to be the opposite of LLY's daily performance, magnified by a factor of one.

Sector Sentiment

Broader sentiment towards the pharmaceutical sector can influence LLY's stock price, impacting ELIS.

Positive news or increased investor confidence in the pharma industry may lift LLY, negatively affecting ELIS; conversely, negative sector news could benefit ELIS.

Key Metrics for ELIS

Risk Factors to Monitor

Single-Stock Concentration
The fund's performance is entirely dependent on the price movements of Eli Lilly and Company (LLY), as it holds a 100% position in the stock. Any adverse news, regulatory changes, or negative developments specific to LLY will directly and significantly impact the fund's value. This concentration amplifies the potential for losses compared to a diversified portfolio.
Compounding Risk
Due to the fund's 1X daily inverse objective, returns are reset daily. This means that the fund's performance over periods longer than one day can deviate significantly from the inverse of LLY's performance due to the effects of compounding. During periods of high volatility, this effect can lead to substantial losses, even if LLY's overall trend is relatively flat.
Volatility Drag
The fund's inverse exposure is particularly vulnerable to volatility. As LLY's price fluctuates, the fund's daily rebalancing can lead to a 'volatility drag,' where the fund loses value even if LLY's price remains relatively unchanged over time. This effect is exacerbated during periods of high market volatility, potentially leading to significant underperformance.
Tracking Error
The fund's ability to perfectly track the inverse performance of LLY is subject to tracking error. This can arise from various factors, including fund expenses, the use of derivatives, and the daily rebalancing process. The fund's performance may deviate from the inverse of LLY's daily returns, leading to unexpected outcomes for investors.
Leverage Decay
The fund's daily reset mechanism means that it is subject to 'beta slippage' or 'decay'. If LLY trends in one direction over a period, the fund will likely underperform its inverse target due to the daily reset. This effect is most pronounced during sustained trends in the underlying asset, leading to losses for the fund.
Expense Ratio Impact
The fund's expense ratio and other structural costs will erode returns over time. These fees are a direct drag on performance, and the fund must generate returns sufficient to cover these costs. If LLY's performance is relatively flat or experiences only modest gains, the fund may still generate losses due to the impact of these expenses.

Frequently Asked Questions

What is the investment objective of ELIS?

What is the structure of the ELIS ETF?

What are the top holdings of ELIS?

What are the risks associated with investing in ELIS?

How does the expense ratio affect ELIS returns?

How volatile is ELIS?

What is the relationship between ELIS and LLY?

What is the 52-week high and low for ELIS?

Who might consider investing in ELIS?

How liquid is ELIS?

ELIS·ELIS

What's happening to ELIS today?

News Sentiment Analysis

Recent News Coverage (Top ETF Holdings)

Discover More

ELIS ETF: Navigating Inverse Exposure to Eli Lilly

Inverse Exposure

Concentrated Holdings

Trading Strategy

Pharma Sector Focus

Risk Considerations

Positioning ELIS

What Influences ELIS?

LLY's Drug Pipeline

Inverse Daily Leverage

Sector Sentiment

Key Metrics for ELIS

Risk Factors to Monitor

Frequently Asked Questions

News Sentiment Analysis

Recent News Coverage (Top ETF Holdings)

Discover More

ELIS ETF: Navigating Inverse Exposure to Eli Lilly

Inverse Exposure

Concentrated Holdings

Trading Strategy

Pharma Sector Focus

Risk Considerations

Positioning ELIS

What Influences ELIS?

LLY's Drug Pipeline

Inverse Daily Leverage

Sector Sentiment

Key Metrics for ELIS

Risk Factors to Monitor

Frequently Asked Questions